Drugs / Akkermansia muciniphila
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07635277 | Mar → Nov 2026 expected | radiodermatitis | West China Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07415473 | Apr 2026 → Mar 2029 expected | Crohn disease | Chinese Medical Association | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05720299 | Mar → Jun 2025 | prediabetes syndrome | Yu Chen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Akkermansia muciniphila | “Inactivated whole-cell Akkermansia muciniphila topical preparation.” NCT07635277 ↗ |
| Known as | AKK | “Akkermansia muciniphila (AKK), a commensal gut bacterium, exhibits anti-inflammatory and barrier-repairing properties via NF-κB, Nrf2, and NLRP3 pathways.” NCT07635277 ↗ |
| Modality | Other / unclassified | “inactivated whole-cell AKK preparation” NCT07635277 ↗ |
| Route | Oral | “receive oral Akkermansia muciniphila once daily” NCT07415473 ↗ |